Abnormal Reactions of Free Radicals and Oxidative Damages in the Bodies of Patients With Chronic Glomerulonephritis

Objective To study the abnormal reactions of a series of free radicals and the oxidative damages induced by free radical abnormal reactions in the bodies of patients with chronic glomerulonephritis. Methods Eighty chronic glomerulonephritis patients (CGNP) and eighty healthy adult volunteers (HAV) were enrolled in a random control study, in which concentrations of nitric oxide (NO) in plasma, lipoperoxides (LPO) in plasma and in erythrocytes, and vitamin C (VC), vitamin E (VE) and beta-carotene (?CAR) in plasma as well as activities of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX) in erythrocytes were determined with spectrophotometric assays. Results Compared with the average values of the above biochemical parameters in the HAV group, the average values of NO in plasma, and LPO in plasma and erythrocytes in the CGNP group were significantly increased (P = 0.0001), while those of VC, VE and -CAR in plasma as well as those of SOD, CAT and GPX in erythrocytes in the CGNP group were significantly decreased (P = 0.0001). Pearson product-moment correlation analysis showed that with increase of the concentration of blood creatinine as well as prolongation of the course of disease in the CGNP, the concentrations of NO in plasma, and LPO in plasma and erythrocytes in the CGNP increased gradually, while the concentrations of VC, VE and ?CAR in plasma as well as the activities of SOD, CAT and GPX in erythrocytes in the CGNP decreased gradually (P = 0.002454 0.000001). The relative risk ratio (RR) of the above biochemical parameters reflecting oxidative damages in the bodies of CGNP ranged from 6.061 to 72.429. The reliability coefficient (alpha) that the above biochemical parameters were used to reflect the oxidative damages of the CGNP was 0.8137, standardized item alpha = 0.9728, Hotelling抯 T-Squared = 1135680.191, F = 53274.6478, P = 0.000001. Conclusions The findings in this study show that in the bodies of CGNP a series of free radical chain reactions result in severe pathological aggravation and induce oxidative damages in their bodies. Therefore, suitable dose of antioxidants should be supplemented to them so as to alleviate oxidative damages in their bodies.

Professor Wang Gang's Experience in Treating Chronic Glomerulonephritis

Prof. Wang Gang, director of the National Center of Nephroses of Jiangsu Provincial TCM Hospital, has engaged for more than 20 years in the treatment of nephroses with traditional Chinese medicine (TCM). The following is a report of Prof. Wang's experience in the TCM differential treatment of chronic glomerulonephritis.

Efficacy and safety of Nephritis rehabilitation tablet combined with Valsartan for chronic glomerulonephritis:A system review and metaanalysis

Objective:To systematically evaluate the efficacy and safety of Nephritis Rehabilitation Tablet(NRT)combined with valsartan in treatment of chronic glomerulonephritis(CGN).Methods:Computer search databases such as CNKI,CBM,VIP,wanfang,Embase,PubMed and Cochrane library,and find all randomized controlled trials(RCTs)comparing NRT combined with valsartan versus valsartan in treatment of chronic glomerulonephritis.The search time limit is to build the database until October 2020.RCTs were screened according to the inclusion and exclusion criteria.After data extraction and quality assessment,the Cochrane risk of bias tool was used to evaluate the methodological quality of these studies.Meta-analysis was performed by Review Manager 5.2,and GRADE system for evidence quality evaluation.Results:We have identified a total of 24 eligible RCTs with 2082 participants and completed a meta-analysis based on these RCTs.The results of the meta-analysis showed that compared with valsartan,NRT combined with valsartan treatment showed effective curative effect in terms of effective treatment rate(OR=4.72;95%CI,3.67,6.08;P<0.00001),24h urine protein quantification(MD=-0.52;95%CI,-0.59,-0.44;P<0.00001),serum creatinine(Scr)(MD=-10.33;95%CI,-14.00,-6.66;P<0.00001),Systolic blood pressure(SBP)(MD=-11.42;95%CI,-17.67,-5.17;P=0.0003),Diastolic blood pressure(DBP)(MD=-6.28;95%CI,-9.14,-3.42;P<0.0001),Blood urine nitrogen(BUN)(MD=-0.02;95%CI,-0.41,0.37;P=0.93),plasma albumin(ALB)(MD=5.05;95%CI,4.27,5.84;P<0.00001),and adverse reactions(OR=0.93,95%CI,0.54,1.60;P=0.78).No serious adverse events were mentioned in these studies.And based on the results of the systematic review,the GRADE system recommended ranking method was used to evaluate the quality of evidence and the recommendation level.The results showed that the level of evidence was moderate and the recommendation intensity was weak recommendation.Conclusions:NRT combined with valsartan has a significant effect on the treatment of CGN,and the treatment effect is better than valsartan alone.There are no obvious adverse reactions during the treatment process.However,due to the generally low quality of the literature included in these studies,and the variability of the evaluation methods of each study,morelarge samples,multi-center,high-quality samples are still needed RCTs are further verified.

Changes of renal function impairment, extracellular matrix regulation, renal fibrosis and inflammation in patients with chronic glomerulonephritis

Objective: To investigate the changes and clinical significance of renal function impairment, extracellular matrix regulation, renal fibrosis and inflammation in patients with chronic glomerulonephritis. Methods: A total of 50 patients with chronic glomerulonephritis admitted to our hospital from May 2016 to February 2018 were selected as observation group and 50 healthy people as control group.The expression levels and related inflammatory markers of renal dysfunction [including Uric acid (UA), retinol binding protein (RBP) and type IV collagen (Col-IV)], extracellular matrix modulation [including tissue inhibitor of metalloproteinase -1 (TIMP-1) and matrix metalloproteinase-9 (MMP-9)], renal fibrosis [including transforming growth factor β1 (TGF-β1), laminin (LN) and hyaluronic acid (HA).] and degree of inflammation [including leukocyte stimulating hormone-1 (Lkn-1) and tumor necrosis factor-α (TNF-α)] were observed and compared between the two groups. Results:The changes of renal function impairment, extracellular matrix regulation, renal fibrosis and inflammation were significant in both groups. Compared with healthy controls in the control group, UA[(352.49±26.57) μmol/L], RBP[(98.75±26.91) mg/L], Col-IV[(224.77±72.32) ng/L], TIMP-1[(145.79±49.67) ng/mL], MMP-9[(177.71±52.35) ng/mL], TGF-β1[(15.23±7.61) ng/mL], LN[(153.82±23.01) μg/L], HA[(366.80±77.98) μg/L], Lkn-1[(82.71±20.64) pmol/L] and TNF-α[(138.01±45.26) pg/mL] levels were significantly elevated. The differences were statistically significant. Conclusions: Chronic glomerulonephritis patients with renal dysfunction and abnormal regulation of extracellular matrix, and severe renal fibrosis, the body is at a higher level of inflammation, clinical indicators should be strengthened to detect the early diagnosis of the disease and treatment basis.

Meta-analysis of the efficacy and safety of Shenkang injection combined with Western medicine in the treatment of chronic glomerulonephritis

Objective:The purpose of the research was to systematically evaluate the clinical efficacy and safety of Shenkang injection combined with Western medicine in treating chronic glomerulonephritis.Methods:Randomized controlled trials of Shenkang Injection combined with Western medicine in treating CGN were obtained from 8 Science databases including China National Knowledge Infrastructure(CNKI),China Biomedical Database(SinMed),Weipu Database(VIP),Wanfang Database(Wanfang),PubMed,The Cochrane Library,Embase,Web of Science from establishment to June 2022.Two researchers screened literature and extracted useful data according to inclusion and exclusion criteria,and used RevMan 5.3 and STATA SE 14.0 software to perform meta-analysis.Results:1,214 patients were included in 15 studies,with 607 in treatment group and 607 in control group.The results of meta-analysis showed that the treatment group could improve the clinical effective rate[RR=1.33,95%CI(1.25,1.40),P<0.00001],reduce serum creatinine[MD=-31.28,95%CI(-42.90,-19.66),P<0.00001],blood urea nitrogen[MD=-2.26,95%CI(-3.08,-1.44),P<0.00001],24-hour urine protein quantification[MD=-0.37,95%CI(-0.49,-0.25),P<0.00001],tumor necrosis factor-α[MD=-7.93,95%CI(-10.56,-5.30),P<0.00001],systolic blood pressure[MD=-10.81,95%CI(-13.66,-7.96),P<0.00001]and diastolic blood pressure[MD=-7.36,95%CI(-9.34,-5.38),P<0.00001].Conclusion:Shenkang injection combined with Western medicine can enhance the clinical effective rate of CGN and reduce the levels of serum creatinine,blood urea nitrogen,24-hour urine protein quantification,tumor necrosis factor-α,systolic blood and diastolic blood pressure.However,due to the low quality of literature,the conclusion still needs to be supported by more multi-center,large-sample studies with rigorous design and standardized implementation.

CGN患者Cys C、NAG、Cr水平的变化及其与肾功能损害的关系

目的探讨慢性肾小球肾炎(CGN)患者治疗前后血浆胱抑素C(Cys C)及尿N-乙酰-β-D氨基葡萄糖苷酶(NAG)、血肌酐(Cr)水平的变化及其与肾功能损害的关系。方法将我院接诊的398例CGN患者纳入CGN组,给予中西结合治疗,另将我院同期健康体检者纳入正常组,比较CNG患者治疗前后血浆Cys C、尿NAG、血Cr水平的变化,并分析其与肾功能损害的关系。结果 CGN组治疗后血浆Cys C、尿NAG、血Cr水平均显著降低(P <0. 05),GFR显著升高(P <0.05);随着肾功能损害的加重,CGN患者血浆Cys C、尿NAG、血Cr水平呈上升趋势(P <0. 05);CGN患者血浆Cys C、尿NAG、血Cr水平与GFR均呈负相关(P<0.05)。结论血浆Cys C、尿NAG、血Cr水平与CGN患者肾功能损害呈正相关,三种指标的监测对CGN诊断和预后评估具有重要临床价值。

宋立群教授治疗CGN门诊病例用药规律的数据挖掘研究

目的:探讨宋立群教授临证治疗慢性肾小球肾炎(chronic glomerulonephritis,CGN)的辨证用药规律,为中医中药治疗CGN提供参考。方法:收集宋立群教授2013年1月~2015年1月期间门诊治疗CGN病例中的首诊方剂,建立数据库,对其用药规律进行剖析。结果:共收集有效病例290例,共涉及用药192味,总使用频次5423次,常用药物33味,药物以补虚药为主,其次为止血药、收涩药及消食药;四气统计,温性药最多,平性药次之;药味使用数最多的是甘味药和苦味药;归经统计,肝经、肾经、脾经的药物最常用。结论:宋立群教授治疗CGN脾肾并重治其本,结合五脏相关,以温补肝肾,健脾益气为其常法,疏肝理气,凉血止血,活血化瘀为其变法。

自拟培土固本方治疗脾肾两虚型CGN的临床分析

目的探讨自拟培土固本方治疗脾肾两虚型慢性肾小球肾炎(chronic glomerulonephritis,CGN)的临床疗效,为临床用药提供参考。方法选取符合诊断标准的100例CGN患者,随机分为治疗组和对照组,各50例。对照组接受西药对症处理,观察组在对照组基础上加以服用自拟培土固本方进行临床疗效对比分析。结果治疗6个月后,治疗组临床显效18例,有效25例,无效7例,总有效率为86. 00%;对照组显效15例,有效22例,无效13例,总有效率74. 00%,两组比较存在显著性差异(P <0. 05)。结论自拟培土固本方治疗脾肾两虚型CGN疗效显著。

Rituximab therapy for primary glomerulonephritis: Report on two cases

The evidence in the medical literature on the efficacy and safety of rituximab therapy for primary glomerulonephritis is limited and controversial. We describe two male Caucasian patients with rapidly progressive kidney failure due to primary proliferative glomerulonephritis. Both of them received high-dose intravenous corticosteroids and oral cyclophosphamide with limited benefit. The first patient(hepatitis C virus-negative mixed cryoglobulinemia) underwent plasma-exchange with intravenous immunoglobulins; he showed significant benefit on kidney function(he became dialysis independent with serum creatinine going back to 1.6 mg/d L) after one rituximab pulse even if urinary abnormalities were still present. No improvement in renal function or urinary changes occurred in the second patient. Both these individuals developed sepsis over the follow-up, the first patient died two months after rituximab therapy. This report is in keeping with the occurrence of severe infections after rituximab therapy in patients with renal impairment at baseline and concomitant high-dose steroids.

Clinical Study on Treatment of Chronic Renal Failure with Shenshuailing

The therapeutic effects of Shenshuailing Kou Fu Ye (SKFY [symbol: see text], the Oral Liquid for Renal Failure) and Shenshuailing Guan Chang Ye (SGCY [symbol: see text], the Enema for Renal Failure) were evaluated in treatment of chronic renal failure, with coateg aldehyde oxystarch as the controls. The changes in the clinical symptoms, serum creatinine, blood urea nitrogen and creatinine clearance rate were observed. The total effective rate in the former was 90.46%, and the latter 60.43%.

Discussion on the medication rule of Professor Ba Yuanming in the treatment of chronic glonerulonephritis based on data mining technology

Objective:To explore the medication rule of Professor Ba Yuanming in the treatment of chronic glonerulonephritis by data mining technology,so as to provide certain reference for clinical and scientific research in the treatment of Chronic glonerulonephritis with traditional Chinese medicine.Methods:collect,sort out and screen the cases of chronic nephritis diagnosed and treated by Professor Ba Yuanming in the outpatient department of Hubei Hospital of traditional Chinese medicine from 2018 to 2019,establish the database on the cloud platform of ancient and modern medical cases(v2.2.1),and use frequency statistics,association rules,hierarchical clustering and other analysis methods to study and analyze the drugs used.Results:1630 cases were included in the prescription,involving 212 traditional Chinese medicines.The high-frequency drugs are Poria cocos,astragalus,dangshen,yam,Chuanshanlong,Cornus,distracted wood,etc;the drugs are mainly warm,cold and calm;the five tastes are sweet and light,spicy and bitter;the meridian tropism is mostly found in the kidney,lung and spleen channels;the effects are calming the mind and the nerves,strengthening the spleen and stomach,promoting water and swelling,etc.The core Chinese medicine combinations of Astragalus and poria were obtained.Conclusion:Professor Ba Yuanming pays attention to comprehensive consideration,attack and supplement in the treatment of CGN,pays attention to the care of the healthy qi of Sanjiao,at the same time clearing away heat and dampness,removing blood stasis and firmness,and is good at using the sweet and gentle products.

A Summary of Lei Genping's Experience in the Treatment of Chronic Nephritis

Chronic glomerulonephritis involves multiple organs.It has a variety of clinical manifestations and is the major cause of progression to end-stage renal disease in patients with kidney disease.Professor Lei Genping believes that the treatment of this disease in Chinese medicine should be based on the deficiency and reality characteristics of the disease mechanism,distinguishing the priorities and identifying the strengths and weaknesses of the internal organs,as well as advocating the integration of Chinese and western medicine at the right time and in the right manner,in order to achieve fundamental results.

温阳补肾汤辅助治疗CGN脾肾阳虚证患者的效果

目的:探讨温阳补肾汤辅助治疗慢性肾小球肾炎(chronic glomerulonephritis,CGN)脾肾阳虚证患者的效果。方法:选取2021年1月—2022年2月山西省中医药研究院100例CGN脾肾阳虚证患者。根据随机数表法将其分为对照组和观察组,各50例。对照组给予常规西药治疗,观察组在常规西药治疗基础上给予温阳补肾汤辅助治疗。比较两组临床疗效,以及治疗前、治疗3个月后肾功能、T淋巴细胞亚群及肝功能损害。结果:观察组总有效率(90.00%)高于对照组(72.00%)(P<0.05)。治疗3个月后,观察组血清中尿素氮(BUN)、肌酐(Scr)、24 h尿蛋白定量(24 h UPQ)水平均低于对照组(P<0.05)。治疗3个月后,观察组 CD8^(+)水平低于对照组,CD4^(+)、CD3^(+)水平均高于对照组(P<0.05)。两组肝功能损害发生率比较差异无统计学意义(χ^(2)=0.000,P=1.000)。结论:温阳补肾汤辅助治疗CGN脾肾阳虚证患者可显著改善肾功能及T淋巴细胞亚群,提高治疗效果,且不会增加肝功能损害情况。

肾炎康复片联合氯沙坦钾片治疗慢性肾小球肾炎研究进展

临床研究发现,肾炎康复片联合氯沙坦钾片能有效减轻肾小球损伤,有助于修复受损肾小球足细胞,能有效降低尿蛋白、尿红细胞、血肌酐等,对治疗慢性肾小球肾炎有较好的预后效果,具有疗效确切、用药安全等优势。此文对慢性肾小球肾炎的中医病因病机、治疗原则加以概述,对肾炎康复片组方机制、氯沙坦钾片作用机制以及联合用药的临床研究进展进行综述,总结肾炎康复片联合氯沙坦钾片治疗慢性肾小球肾炎的经验。

慢性肾小球肾炎患者MCP-1和sFlt-1表达与肾功能及预后的相关性研究

目的:分析慢性肾小球肾炎患者血清单核细胞趋化蛋白-1(MCP-1)和可溶性血管内皮细胞生长因子受体1(sFlt-1)水平变化及其与肾功能和预后的关系。方法:纳入2018-01—2020-03本院收治的慢性肾小球肾炎患者122例(研究组),选取同时期本院体检健康者128例(对照组)。研究组依据肾功能损害情况分为A组(肾功能正常16例)、B组(轻中度肾功能损害88例)、C组(重度肾功能损害18例);根据随访结局,将患者分为肾功能衰竭组(22例)和病情缓解组(100例)。采用酶联免疫吸附法(ELISA)检测受试者MCP-1、sFlt-1水平。采用全自动生化分析仪检测所有受试者血尿素氮(BUN)、血肌酐(Scr)水平,采用慢性肾脏疾病流行病学合作研究公式(CKD-EPI)估算肾小球滤过率(eGFR)。Pearson法分析MCP-1、sFlt-1与BUN、Scr、eGFR的相关性。采用受试者工作特征(ROC)曲线评价血清MCP-1、sFlt-1水平预测慢性肾小球肾炎患者预后的价值。结果:与对照组相比,研究组MCP-1、sFlt-1、BUN、Scr水平较高(P<0.05),eGFR较低(P<0.05)。C组BUN、Scr、MCP-1、sFlt-1水平明显高于A组、B组(P<0.05),B组BUN、Scr、MCP-1、sFlt-1水平明显高于A组(P<0.05)。Pearson相关性分析显示,MCP-1与BUN、Scr均呈正相关(P<0.05),与eGFR呈负相关(P<0.05),sFlt-1与BUN、Scr均呈正相关(P<0.05),与eGFR呈负相关(P<0.05)。与病情缓解组相比,肾功能衰竭组患者清中MCP-1、sFlt-1水平较高(P<0.05)。ROC分析显示,血清MCP-1、sFlt-1水平预测慢性肾小球肾炎患者预后的AUC分别为0.967、0.965,MCP-1联合sFlt-1预测慢性肾小球肾炎患者预后的AUC为0.984,灵敏度100.00%,特异度94.00%。结论:慢性肾小球肾炎患者血清MCP-1、sFlt-1水平明显上升,可作为患者预后评估的潜在生物学指标。

基于名中医经验的中医辨证组方治疗老年慢性肾炎(CKD1~3a期)患者随机对照研究

目的:观察基于名中医经验的中医辨证组方对老年慢性肾炎(CKD1-3a期)患者的有效性和安全性。方法:将84例老年慢性肾炎患者随机分成治疗组(42例)和对照组(42例)。治疗组采用西医基础联合中医辨证组方治疗;对照组仅接受西医基础治疗,疗程均为24周。观察两组治疗前后24 h尿蛋白定量(24 h UPQ)、肾小球滤过率(eGFR)等临床指标变化,以及疗效和安全性。结果:与本组基线比较,两组治疗后12、18、24周24 h UPQ均显著下降(P<0.01),且24周时治疗组优于对照组(P<0.01)。治疗组总有效率为67.57%,对照组总有效率41.67%,治疗组显著高于对照组(P<0.05)。将慢性肾脏病(CKD)3a期患者进行亚组分析提示,24周后治疗组eGFR较本组基线及同期对照组显著升高(P<0.01,P<0.05),而对照组治疗前后无显著变化。治疗组不良反应发生4例,对照组2例,两组无严重不良反应出现。结论:基于名中医经验的中医辨证组方治疗老年慢性肾炎(CKD1-3a期),可减少尿蛋白,提高临床疗效,对其中的CKD3a期患者可能具有改善eGFR作用,且安全性较好。

慢性肾小球肾炎中西医结合治疗研究进展

慢性肾小球肾炎是一种常见的原发性肾小球疾病。该疾病通常导致肾功能逐步退化,并可能引发蛋白尿、血尿、高血压和水肿等一系列症状,严重时甚至可能进展为慢性肾衰竭和重度贫血,严重影响患者的健康和日常生活。传统治疗方案主要依赖于降压药物、激素和细胞毒性药物,以缓解肾功能的进一步恶化。近年来,随着中医学的不断发展,中医辨证施治理念开始应用于慢性肾小球肾炎的治疗实践中,能够有效缓解血尿、水肿和高血压等症状。中西医联合治疗较单纯西药治疗慢性肾小球肾炎在疗效上具有更大的优势,且能够减少毒副作用。为进一步提升临床治疗效果,现代医学与中医学的结合治疗模式被广泛采用,这种跨学科的合作能够有效提升慢性肾小球肾炎的治疗效果,不仅能减轻患者的症状,改善肾功能,还能有效延缓慢性肾衰竭的进程,从而提高患者的生活质量。本文对慢性肾小球肾炎中西医结合治疗的研究进展进行综述,以期为慢性肾小球肾炎的临床治疗提供参考。

黄蛭益肾胶囊联合阿魏酸哌嗪片治疗慢性肾小球肾炎临床研究

目的:观察黄蛭益肾胶囊联合阿魏酸哌嗪片治疗慢性肾小球肾炎的临床疗效。方法:按随机数字表法将96例慢性肾小球肾炎患者分为2组各48例。西药组给予阿魏酸哌嗪片治疗,联合组给予黄蛭益肾胶囊联合阿魏酸哌嗪片治疗。比较2组治疗前后中医证候积分、T淋巴细胞亚群及肾功能指标,比较2组临床疗效与不良反应。结果:联合组总有效率97.92%,高于西药组85.42%(P<0.05)。治疗后,2组中医证候积分均降低(P<0.05),且联合组低于西药组(P<0.05)。治疗后,2组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均升高(P<0.05),CD8^(+)降低(P<0.05),且联合组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于西药组(P<0.05),CD8^(+)低于西药组(P<0.05)。治疗后,2组血清尿素氮(BUN)、血肌酐(SCr)、肾小球滤过率(GFR)均降低(P<0.05),且联合组低于西药组(P<0.05)。联合组不良反应发生率4.17%,低于西药组18.75%(P<0.05)。结论:黄蛭益肾胶囊联合阿魏酸哌嗪片治疗慢性肾小球肾炎能提高临床疗效,改善肾功能与免疫功能,安全性高。

循证护理在慢性肾小球肾炎中的应用探究

目的 分析循证护理模式在慢性肾小球肾炎患者临床干预中的价值。方法 选择医院于2023年2月至2023年8月间收治的70例慢性肾小球肾炎患者为观察对象,经随机分组后,观察组患者实施循证护理,对照组患者实施常规护理干预,评估两组患者的护理效果差异。结果 观察组患者自我管理能力、生活质量评分高于对照组,睡眠障碍评分与心理状态评分低于对照组(P<0.05)。结论 在慢性肾小球肾炎患者临床干预阶段,循证护理成为强化患者自我管理能力、消除负面情绪的重要组成部分,其临床护理效果显著,值得推广。

肾衰宁胶囊联合氯沙坦钾在慢性肾小球肾炎中的应用进展

慢性肾小球肾炎,也被称为慢性肾炎,属于肾脏疾病中的慢性进展性疾病,会导致肾功能逐渐丧失。近年来,肾衰宁胶囊联合氯沙坦钾的应用在临床治疗中展现出卓越的效果,该用药方案不仅改善了患者的临床症状,还显著降低了中医证候积分,为慢性肾小球肾炎的治疗提供了新的参考路径。肾衰宁胶囊是一种中成药,具有利尿、降压的作用,而氯沙坦钾是一种能够阻断血管紧张素Ⅱ与其受体结合的药物,具有降低血压的作用。两种药物的联合应用可以有效降低血压,改善肾功能,从而减轻慢性肾小球肾炎对肾脏的损害。随着联合药物的应用也在最新研究中得到进一步的发展,越来越多的研究表明,上述药物的联合应用可以显著改善肾功能,降低尿蛋白和血尿的发生率,从而为患者提供更好的治疗效果。因此,对肾衰宁胶囊联合氯沙坦钾治疗慢性肾小球肾炎的效果进行分析有着重要意义。